Navigation Links
Mayo Clinic Study Finds FDA Warning Against Anti-Nausea Drug Droperidol Unnecessary
Date:9/28/2007

ROCHESTER, Minn., Sept. 28 /PRNewswire-USNewswire/ -- A Mayo Clinic review of patients' responses to a drug used to control nausea and vomiting during anesthesia for general surgery questions a U.S. Food and Drug Administration (FDA) warning against the drug's use. This study appears in the current issue of the journal Anesthesiology.

The FDA warning against droperidol was prompted in 2001 over concerns that the drug contributed to potentially fatal heart rhythm abnormalities. Mayo Clinic compared 139,932 patients' responses before the warning was issued (and droperidol was used) and found no proven cases of complications directly attributable to droperidol. In comparison, after the FDA warning, two of 151,256 patients had poor heart rhythm while receiving other, more expensive medication alternatives. The percentage of patients who received droperidol was 12 percent prior to the warning and 0 percent after placement of the warning.

Based on their findings, Mayo Clinic anesthesiologists conclude that the FDA warning against droperidol is unnecessary. They call for other investigators to study the topic to determine if further inquiry supports that conclusion.

"In our study, we obtained results that were just the opposite of what the FDA action would predict. We actually had fewer complications with droperidol," explains Gregory Nuttall, M.D., the lead Mayo Clinic anesthesiologist on the study. "In our experience, low-doses of droperidol used by a skilled team are the safer and more effective agent for controlling nausea and vomiting, which is why we are making plans to resume its low-dose use in select patients in the cardiac Intensive Care Unit."

Significance of the Mayo Clinic Study

The Mayo Clinic study is the first large, statistically well-controlled study of patient responses to droperidol at a single medical center over a long time (three years) that included treatment before and after the FDA warning. As such, it pro
'/>"/>

SOURCE Mayo Clinic
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Genetic Analysis Systems Enter the Clinical Mainstream
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Large Geographic Differences in EpiPen Prescriptions in the U.S., From the Journal of Allergy and Clinical Immunology
4. Sygnis Pharma AG announces date for presentation of clinical results
5. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Clinical Data Suggest Decreased Bleeding Risk in People With Severe Hemophilia A While Maintaining Factor VIII Levels Above One Percent
7. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
8. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
9. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. Protox Announces Positive Clinical Data from Prostate Cancer Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... Calif. , Aug. 31, 2015  QT Vascular Ltd., ... Vascular", and together with its subsidiaries, the "Group"), ... and distribution of advanced therapeutic solutions for the ... the final results of the below-the-knee ("BTK") cohort ... ("BAR") which were presented on August 15, 2015 ...
(Date:8/31/2015)... -- Bionomics Limited (ASX:BNO, ADR:BMICY), a biopharmaceutical company focused ... the treatment of diseases of the central nervous system ... submission has passed review by the US Food and ... 1 clinical trial in patients with metastatic colon cancer ... 31 December 2015. Bionomics, CEO & Managing ...
(Date:8/31/2015)... Wash. , Aug. 31, 2015   ... the leading developer, manufacturer and marketer of proprietary ... and cryopreservation freeze media and ... management app for smart shippers ... customer TiGenix NV, an advanced biopharmaceutical company focused ...
Breaking Medicine Technology:Final Results From Below-The-Knee Cohort In Chocolate Registry Presented At The 5th Annual Amputation Prevention Conference 2Final Results From Below-The-Knee Cohort In Chocolate Registry Presented At The 5th Annual Amputation Prevention Conference 3Final Results From Below-The-Knee Cohort In Chocolate Registry Presented At The 5th Annual Amputation Prevention Conference 4Successful BNC101 IND Submission Paves Way for Development of Promising Cancer Stem Cell Drug Candidate 2Successful BNC101 IND Submission Paves Way for Development of Promising Cancer Stem Cell Drug Candidate 3Successful BNC101 IND Submission Paves Way for Development of Promising Cancer Stem Cell Drug Candidate 4BioLife Solutions Customer TiGenix Phase 3 Clinical Trial Meets Primary Endpoint 2BioLife Solutions Customer TiGenix Phase 3 Clinical Trial Meets Primary Endpoint 3BioLife Solutions Customer TiGenix Phase 3 Clinical Trial Meets Primary Endpoint 4BioLife Solutions Customer TiGenix Phase 3 Clinical Trial Meets Primary Endpoint 5
... WARREN, N.J., March 30, 2011 MonoSol Rx, ... delivery company specializing in proprietary pharmaceutical film products, ... drug (IND) meeting with the U.S. Food and ... Sodium Oral Soluble Film (OSF) under a 505(b)(2) ...
... SHELTON, Conn., March 30, 2011 Cara Therapeutics, Inc. ... Pharm.D., to the position of Chief Medical Officer.  In ... development of Cara,s lead drug candidate, CR845, a novel, ... 2 development for treatment of post-operative pain. ...
Cached Medicine Technology:MonoSol Rx Secures 505(b)(2) Regulatory Pathway for Montelukast Sodium Oral Soluble Film 2MonoSol Rx Secures 505(b)(2) Regulatory Pathway for Montelukast Sodium Oral Soluble Film 3Cara Therapeutics Announces Appointment of James B. Jones, M.D., Pharm.D., as Chief Medical Officer 2Cara Therapeutics Announces Appointment of James B. Jones, M.D., Pharm.D., as Chief Medical Officer 3
(Date:8/31/2015)... (PRWEB) , ... August 31, ... ... information security executive networking and relationship-marketing firm, announced today the nominees vying ... in the Northeast U.S. Region. Executives include top-ranking decision makers representing national ...
(Date:8/31/2015)... ... August 31, 2015 , ... ... collection, cloud analytics and workflow solutions will demonstrate multiple prototypes from its Innovation ... September 22-24, 2015. This is the only European event dedicated to providing case ...
(Date:8/31/2015)... ... August 31, 2015 , ... Intellitec Solutions announced they have reached a ... their 8th new staff member in 2015. With the potential for more hiring occurring ... supports Microsoft Dynamics GP, Dynamics SL, Dynamics CRM and Intacct, and has hired new ...
(Date:8/31/2015)... ... August 31, 2015 , ... Thermi, ... health, is proud to announce South Korea’s Ministry of Food and Drug ... the most sought-after radio frequency thermotherapy technology available in United States, South Korea, ...
(Date:8/31/2015)... ... , ... The Marietta dentists and staff at Verde Pointe Dental ... and staff ran a 5K race, the Iron Horse for Enduring Hearts on August ... sponsored the event to help support projects with funding to increase understanding of clinical ...
Breaking Medicine News(10 mins):Health News:T.E.N. Announces Nominees for the 2015 ISE® Northeast Awards; People's Choice voting now open 2Health News:T.E.N. Announces Nominees for the 2015 ISE® Northeast Awards; People's Choice voting now open 3Health News:T.E.N. Announces Nominees for the 2015 ISE® Northeast Awards; People's Choice voting now open 4Health News:ERT to Demonstrate Innovation Lab Prototypes at European PRO / eCOA Congress 2Health News:ERT to Demonstrate Innovation Lab Prototypes at European PRO / eCOA Congress 3Health News:Intellitec Solutions Achieves Record Pace for New Hiring 2Health News:Thermi Heats Up South Korea Announcing Global Expansion with NewRegulatory Approvals for ThermiRF™ 2Health News:Verde Pointe Dental Associates Runs a 5K for Enduring Hearts 2
... and the elderly have slower response times when they have ... research suggests that much of that slower response is a ... healthy older people can be trained to respond faster in ... cognitive skills in this area aren,t so different from younger ...
... celiac disease -- an autoimmune disorder associated with a ... than the general population to report symptoms of depression ... gluten-free diet, according to researchers at Penn State, Syracuse ... often suffer from abdominal pain, constipation, decreased appetite, diarrhea, ...
... Teens are more likely to be obese if they had ... toddlers, according to a new study. The findings echo ... ties with their parents were more likely to be obese ... the latest study, researchers examined U.S. National Institute of Child ...
... -- Quitting smoking is one of the most common ... with six of 10 smokers requiring multiple attempts before ... Association. However, preparing a quit-smoking plan can greatly ... the single most important step smokers can take to ...
... The quality of the emotional relationship between a mother ... that child to be obese during adolescence, a new ... characteristics between mothers and their children during their toddler ... terms of the child,s emotional security and the mother,s ...
... team of neuroscientists, led by researchers at Mayo Clinic ... brain disorder that may be much more common than once ... Nature Genetics , the researchers say they identified 14 ... of hereditary diffuse leukoencephalopathy with spheroids (HDLS). This ...
Cached Medicine News:Health News:Elderly can be as fast as young in some brain tasks, study shows 2Health News:Elderly can be as fast as young in some brain tasks, study shows 3Health News:Elderly can be as fast as young in some brain tasks, study shows 4Health News:Women with celiac disease suffer from depression, disordered eating 2Health News:Women with celiac disease suffer from depression, disordered eating 3Health News:Mother-Toddler Bond May Influence Teen Obesity 2Health News:How to Make Your Quit-Smoking Resolution Stick 2Health News:Study links quality of mother-toddler relationship to teen obesity 2Health News:Study links quality of mother-toddler relationship to teen obesity 3Health News:Study links quality of mother-toddler relationship to teen obesity 4Health News:'Rare' brain disorder may be more common than thought, say Mayo Clinic scientists 2Health News:'Rare' brain disorder may be more common than thought, say Mayo Clinic scientists 3
... 1-step, hand-held, point-of-care device for the qualitative detection ... The TOX/See device can detect up to ... 3 to 8 minutes and requires only a ... individually packaged to maximize convenience and ease of ...
... a 1-step, hand-held, point-of-care device for the qualitative ... urine. The TOX/See device can detect up ... in 3 to 8 minutes and requires only ... is individually packaged to maximize convenience and ease ...
... a 1-step, hand-held, point-of-care device for the qualitative ... urine. The TOX/See device can detect up ... in 3 to 8 minutes and requires only ... is individually packaged to maximize convenience and ease ...
... is a 1-step, hand-held, point-of-care device for the ... human urine. The TOX/See device can detect ... drugs in 3 to 8 minutes and requires ... cassette is individually packaged to maximize convenience and ...
Medicine Products: